サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：動物用抗感染症薬の世界市場 - 世界の業界分析、規模、シェア、成長、動向、予測（2031年）- 種タイプ別、薬剤クラス別、投与モード別、流通チャネル別、地域別
市場調査レポート
商品コード
1394132

動物用抗感染症薬の世界市場 - 世界の業界分析、規模、シェア、成長、動向、予測（2031年）- 種タイプ別、薬剤クラス別、投与モード別、流通チャネル別、地域別

Veterinary Anti-Infectives Market - Global Industry Analysis, Size, Share, Growth, Trends, & Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America & Middle East & Africa)

出版日
ページ情報
英文 232 Pages
納期
2～5営業日
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
動物用抗感染症薬の世界市場 - 世界の業界分析、規模、シェア、成長、動向、予測（2031年）- 種タイプ別、薬剤クラス別、投与モード別、流通チャネル別、地域別
出版日: 2023年12月05日
発行: Fairfield Market Research
ページ情報: 英文 232 Pages
納期: 2～5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

世界の動物用抗感染症薬の市場規模は、北米が最も収益性の高い地域となるなど、勢力図が大きく変化しています。この動向は、ペット飼育の増加、動物栄養強化に対する需要の高まり、食品安全への関心の高まりに起因しています。さらに、ペット保険の導入は増加傾向にあり、米国での加入率は年率10％という驚異的な伸びを示しています。

北米市場は米国がリードしており、予測期間中に75％以上のシェアが見込まれます。カナダもCAGR 4%と予測され、力強い成長を見せています。北米の市場規模シェアは15億米ドルを超えると予想されます。

一方、アジア太平洋は、小動物ケアの促進、畜産部門の繁栄、インドでの販売提携に注力する主要企業によって急速な成長を遂げています。

世界の動物用抗感染症薬市場をリードするのは抗菌剤セグメントで、僅差で抗ウイルス剤が続きます。抗菌剤カテゴリーでは、ペニシリン系、セファロスポリン系、テトラサイクリン系が高い成長率を占めています。抗ウイルス剤セグメントは、薬剤クラス別で2番目に有利なセグメントになると予測され、評価期間中の市場魅力度指数は1.2です。

生物製剤と専門医療は、世界の動物用抗感染症薬市場の主要参入企業にとって大きなビジネスチャンスとなります。研究開発に対する過去の低収益が、新製品開発（NPD）の需要に拍車をかけています。研究開発、特に生物製剤と専門医療における革新は、多くの機会を提供しています。さらに、治療薬の価格が手ごろになり、ペットケアや家畜に対する消費者の意識が高まっていることも、特に新規参入企業にとっては大きな成長見通しにつながっています。

当レポートでは、世界の動物用抗感染症薬市場について調査し、市場の概要とともに、種タイプ別、薬剤クラス別、投与モード別、流通チャネル別、地域別動向、および市場に参入する企業の競合動向などを提供しています。

目次

第1章 エグゼクティブサマリー

第2章 市場概要

  • 市場の定義とセグメンテーション
  • 市場力学
  • バリューチェーン分析
  • ポーターのファイブフォース分析
  • COVID-19の影響分析
  • ウクライナとロシアの紛争の影響
  • 経済概要
  • PESTLE分析

第3章 世界の動物用抗感染症薬市場の見通し、2018年～2031年

  • 世界の動物用抗感染症薬市場の見通し、種タイプ別、金額（100万米ドル）、2018年～2031年
  • 世界の動物用抗感染症薬市場の見通し、薬剤クラス別、金額（100万米ドル）、2018年～2031年
  • 世界の動物用抗感染症薬市場の見通し、投与方法別、金額（100万米ドル）、2018年～2031年
  • 世界の動物用抗感染症薬市場の見通し、流通チャネル別、金額（100万米ドル）、2018年～2031年
  • 世界の動物用抗感染症薬市場の見通し、地域別、金額（100万米ドル）、2018年～2031年

第4章 北米の動物用抗感染症薬市場の見通し、2018年～2031年

第5章 欧州の動物用抗感染症薬市場の見通し、2018年～2031年

第6章 アジア太平洋の動物用抗感染症薬市場の見通し、2018年～2031年

第7章 ラテンアメリカの動物用抗感染症薬市場の見通し、2018年～2031年

第8章 中東・アフリカの動物用抗感染症薬市場の見通し、2018年～2031年

第9章 競合情勢

  • 投与モード別と薬剤クラス別のヒートマップ
  • メーカーと薬剤クラス別のヒートマップ
  • 企業の市場シェア分析、2023年
  • 競争力ダッシュボード
  • 企業プロファイル
    • Bayer AG
    • Cipla Limited
    • Dechra Pharmaceuticals PLC
    • Eli Lilly and Company (Elanco Animal Health)
    • Heska Corp (Diamond Animal Health)
    • Merck & Co., Inc. (Merck Animal Health)
    • Neogen Corporation
    • Phibro Animal Health Corporation
    • Sanofi (Merial Animal Health)
    • Vetoquinol S.A.
    • Virbac S.A.
    • Zoetis, Inc.
    • Boehringer Ingelheim GmbH
    • Ceva Sante Animale
    • Indian Immunologicals Limited
    • Intas Pharmaceuticals Limited
    • Norbrook Laboratories Limited
    • Zydus Animal Health Limited
    • Ashish Life Science Private Limited
    • Oceanic Pharmachem Private Limited.

第10章 付録

目次

The global veterinary anti-infectives market is witnessing a significant shift in dynamics, with North America emerging as the most lucrative region. This trend can be attributed to the increasing pet ownership, a rising demand for enhanced animal nutrition, and a heightened focus on food safety. Furthermore, the adoption of pet insurance is on the rise, with enrollment in the United States growing at an impressive 10% per year.

North America: A Lucrative Hub The United States market leads the way in North America, expected to represent over 75% share during the forecast period. Canada is also set to exhibit robust growth with a projected CAGR of 4%. North America is expected to reach a market value share of more than US$ 1500 Mn.

Asia Pacific: Rapid Expansion Meanwhile, the Asia Pacific (APAC) region is experiencing rapid growth driven by the promotion of small animal care, a thriving livestock segment, and key players focusing on distribution partnerships in India.

Segment Insights: The antimicrobial agents segment leads the global veterinary anti-infectives market, closely followed by antiviral agents. Within the antimicrobial agents category, Penicillins, Cephalosporins, and Tetracyclines account for a higher growth rate. The antiviral agents segment is anticipated to be the second most lucrative segment by drug class, showcasing a market attractiveness index of 1.2 during the assessment period.

Unveiling Opportunities Biologics and specialty care present significant opportunities for key players in the global veterinary anti-infectives market. Past low returns on research and development have spurred a demand for New Product Development (NPD). Innovation in research and development, particularly in biologics and specialty care, offers a plethora of opportunities. Moreover, the increasing affordability of therapeutics and growing consumer awareness about pet care and livestock contribute to significant growth prospects, especially for new market entrants.

Comprehensive Market Segmentation The veterinary anti-infectives market research report provides a comprehensive segmentation based on several attributes:

1. By Region:

  • North America
  • Latin America
  • Europe
  • Asia Pacific (APAC)
  • Middle East and Africa (MEA)

2. By Species Type:

  • Livestock Animals
  • Companion Animals

3. By Drug Class:

  • Antimicrobial Agents
  • Tetracyclines
  • Penicillins
  • Cephalosporins
  • Macrolides
  • Quinolones
  • Others
  • Antiviral Agents
  • Antifungal Agents
  • Antiparasitic Agents
  • Others

4. By Mode of Administration:

  • Oral
  • Parenteral
  • Topical

5. By Distribution Channel:

  • Veterinary Hospitals
  • Veterinary Clinics
  • Pharmacies
  • Others

These segmentation attributes enable a deeper understanding of market dynamics, regional variations, sub-segment analysis, and more.

Table of Contents

1. Executive Summary

  • 1.1. Global Veterinary Anti-Infectives Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value and Volume, 2023
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. COVID-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Impact of Ukraine-Russia Conflict
  • 2.7. Economic Overview
    • 2.7.1. World Economic Projections
  • 2.8. PESTLE Analysis

3. Global Veterinary Anti-Infectives Market Outlook, 2018 - 2031

  • 3.1. Global Veterinary Anti-Infectives Market Outlook, by Species Type, Value (US$ Mn), 2018 - 2031
    • 3.1.1. Key Highlights
      • 3.1.1.1. Livestock Animals
      • 3.1.1.2. Companion Animals
  • 3.2. Global Veterinary Anti-Infectives Market Outlook, by Drug Class, Value (US$ Mn), 2018 - 2031
    • 3.2.1. Key Highlights
      • 3.2.1.1. Antimicrobial Agents
        • 3.2.1.1.1. Tetracyclines
        • 3.2.1.1.2. Penicillins
        • 3.2.1.1.3. Cephalosporins
        • 3.2.1.1.4. Macrolides
        • 3.2.1.1.5. Quinolones
        • 3.2.1.1.6. Others
      • 3.2.1.2. Antiviral Agents
      • 3.2.1.3. Antifungal Agents
      • 3.2.1.4. Antiparasitic Agents
      • 3.2.1.5. Others
  • 3.3. Global Veterinary Anti-Infectives Market Outlook, by Mode of Administration, Value (US$ Mn), 2018 - 2031
    • 3.3.1. Key Highlights
      • 3.3.1.1. Oral
      • 3.3.1.2. Parenteral
      • 3.3.1.3. Topical
  • 3.4. Global Veterinary Anti-Infectives Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 3.4.1. Key Highlights
      • 3.4.1.1. Veterinary Hospitals
      • 3.4.1.2. Veterinary Clinics
      • 3.4.1.3. Pharmacies
      • 3.4.1.4. Others
  • 3.5. Global Veterinary Anti-Infectives Market Outlook, by Region, Value (US$ Mn), 2018 - 2031
    • 3.5.1. Key Highlights
      • 3.5.1.1. North America
      • 3.5.1.2. Europe
      • 3.5.1.3. Asia Pacific
      • 3.5.1.4. Latin America
      • 3.5.1.5. Middle East & Africa

4. North America Veterinary Anti-Infectives Market Outlook, 2018 - 2031

  • 4.1. North America Veterinary Anti-Infectives Market Outlook, by Species Type, Value (US$ Mn), 2018 - 2031
    • 4.1.1. Key Highlights
      • 4.1.1.1. Livestock Animals
      • 4.1.1.2. Companion Animals
  • 4.2. North America Veterinary Anti-Infectives Market Outlook, by Drug Class, Value (US$ Mn), 2018 - 2031
    • 4.2.1. Key Highlights
      • 4.2.1.1. Antimicrobial Agents
        • 4.2.1.1.1. Tetracyclines
        • 4.2.1.1.2. Penicillins
        • 4.2.1.1.3. Cephalosporins
        • 4.2.1.1.4. Macrolides
        • 4.2.1.1.5. Quinolones
        • 4.2.1.1.6. Others
      • 4.2.1.2. Antiviral Agents
      • 4.2.1.3. Antifungal Agents
      • 4.2.1.4. Antiparasitic Agents
      • 4.2.1.5. Others
  • 4.3. North America Veterinary Anti-Infectives Market Outlook, by Mode of Administration, Value (US$ Mn), 2018 - 2031
    • 4.3.1. Key Highlights
      • 4.3.1.1. Oral
      • 4.3.1.2. Parenteral
      • 4.3.1.3. Topical
  • 4.4. North America Veterinary Anti-Infectives Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 4.4.1. Key Highlights
      • 4.4.1.1. Veterinary Hospitals
      • 4.4.1.2. Veterinary Clinics
      • 4.4.1.3. Pharmacies
      • 4.4.1.4. Others
  • 4.5. North America Veterinary Anti-Infectives Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 4.5.1. Key Highlights
      • 4.5.1.1. U.S. Veterinary Anti-Infectives Market by Species Type, Value (US$ Mn), 2018 - 2031
      • 4.5.1.2. U.S. Veterinary Anti-Infectives Market by Drug Class, Value (US$ Mn), 2018 - 2031
      • 4.5.1.3. U.S. Veterinary Anti-Infectives Market by Mode of Administration, Value (US$ Mn), 2018 - 2031
      • 4.5.1.4. U.S. Veterinary Anti-Infectives Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 4.5.1.5. Canada Veterinary Anti-Infectives Market by Species Type, Value (US$ Mn), 2018 - 2031
      • 4.5.1.6. Canada Veterinary Anti-Infectives Market by Drug Class, Value (US$ Mn), 2018 - 2031
      • 4.5.1.7. Canada Veterinary Anti-Infectives Market by Mode of Administration, Value (US$ Mn), 2018 - 2031
      • 4.5.1.8. Canada Veterinary Anti-Infectives Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 4.5.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Veterinary Anti-Infectives Market Outlook, 2018 - 2031

  • 5.1. Europe Veterinary Anti-Infectives Market Outlook, by Species Type, Value (US$ Mn), 2018 - 2031
    • 5.1.1. Key Highlights
      • 5.1.1.1. Livestock Animals
      • 5.1.1.2. Companion Animals
  • 5.2. Europe Veterinary Anti-Infectives Market Outlook, by Drug Class, Value (US$ Mn), 2018 - 2031
    • 5.2.1. Key Highlights
      • 5.2.1.1. Antimicrobial Agents
        • 5.2.1.1.1. Tetracyclines
        • 5.2.1.1.2. Penicillins
        • 5.2.1.1.3. Cephalosporins
        • 5.2.1.1.4. Macrolides
        • 5.2.1.1.5. Quinolones
        • 5.2.1.1.6. Others
      • 5.2.1.2. Antiviral Agents
      • 5.2.1.3. Antifungal Agents
      • 5.2.1.4. Antiparasitic Agents
      • 5.2.1.5. Others
  • 5.3. Europe Veterinary Anti-Infectives Market Outlook, by Mode of Administration, Value (US$ Mn), 2018 - 2031
    • 5.3.1. Key Highlights
      • 5.3.1.1. Oral
      • 5.3.1.2. Parenteral
      • 5.3.1.3. Topical
  • 5.4. Europe Veterinary Anti-Infectives Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 5.4.1. Key Highlights
      • 5.4.1.1. Veterinary Hospitals
      • 5.4.1.2. Veterinary Clinics
      • 5.4.1.3. Pharmacies
      • 5.4.1.4. Others
  • 5.5. Europe Veterinary Anti-Infectives Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 5.5.1. Key Highlights
      • 5.5.1.1. Germany Veterinary Anti-Infectives Market by Species Type, Value (US$ Mn), 2018 - 2031
      • 5.5.1.2. Germany Veterinary Anti-Infectives Market by Drug Class, Value (US$ Mn), 2018 - 2031
      • 5.5.1.3. Germany Veterinary Anti-Infectives Market by Mode of Administration, Value (US$ Mn), 2018 - 2031
      • 5.5.1.4. Germany Veterinary Anti-Infectives Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 5.5.1.5. U.K. Veterinary Anti-Infectives Market by Species Type, Value (US$ Mn), 2018 - 2031
      • 5.5.1.6. U.K. Veterinary Anti-Infectives Market by Drug Class, Value (US$ Mn), 2018 - 2031
      • 5.5.1.7. U.K. Veterinary Anti-Infectives Market by Mode of Administration, Value (US$ Mn), 2018 - 2031
      • 5.5.1.8. U.K. Veterinary Anti-Infectives Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 5.5.1.9. France Veterinary Anti-Infectives Market by Species Type, Value (US$ Mn), 2018 - 2031
      • 5.5.1.10. France Veterinary Anti-Infectives Market by Drug Class, Value (US$ Mn), 2018 - 2031
      • 5.5.1.11. France Veterinary Anti-Infectives Market by Mode of Administration, Value (US$ Mn), 2018 - 2031
      • 5.5.1.12. France Veterinary Anti-Infectives Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 5.5.1.13. Italy Veterinary Anti-Infectives Market by Species Type, Value (US$ Mn), 2018 - 2031
      • 5.5.1.14. Italy Veterinary Anti-Infectives Market by Drug Class, Value (US$ Mn), 2018 - 2031
      • 5.5.1.15. Italy Veterinary Anti-Infectives Market by Mode of Administration, Value (US$ Mn), 2018 - 2031
      • 5.5.1.16. Italy Veterinary Anti-Infectives Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 5.5.1.17. Turkey Veterinary Anti-Infectives Market by Species Type, Value (US$ Mn), 2018 - 2031
      • 5.5.1.18. Turkey Veterinary Anti-Infectives Market by Drug Class, Value (US$ Mn), 2018 - 2031
      • 5.5.1.19. Turkey Veterinary Anti-Infectives Market by Mode of Administration, Value (US$ Mn), 2018 - 2031
      • 5.5.1.20. Turkey Veterinary Anti-Infectives Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 5.5.1.21. Russia Veterinary Anti-Infectives Market by Species Type, Value (US$ Mn), 2018 - 2031
      • 5.5.1.22. Russia Veterinary Anti-Infectives Market by Drug Class, Value (US$ Mn), 2018 - 2031
      • 5.5.1.23. Russia Veterinary Anti-Infectives Market by Mode of Administration, Value (US$ Mn), 2018 - 2031
      • 5.5.1.24. Russia Veterinary Anti-Infectives Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 5.5.1.25. Rest of Europe Veterinary Anti-Infectives Market by Species Type, Value (US$ Mn), 2018 - 2031
      • 5.5.1.26. Rest of Europe Veterinary Anti-Infectives Market by Drug Class, Value (US$ Mn), 2018 - 2031
      • 5.5.1.27. Rest of Europe Veterinary Anti-Infectives Market by Mode of Administration, Value (US$ Mn), 2018 - 2031
      • 5.5.1.28. Rest of Europe Veterinary Anti-Infectives Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 5.5.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Veterinary Anti-Infectives Market Outlook, 2018 - 2031

  • 6.1. Asia Pacific Veterinary Anti-Infectives Market Outlook, by Species Type, Value (US$ Mn), 2018 - 2031
    • 6.1.1. Key Highlights
      • 6.1.1.1. Livestock Animals
      • 6.1.1.2. Companion Animals
  • 6.2. Asia Pacific Veterinary Anti-Infectives Market Outlook, by Drug Class, Value (US$ Mn), 2018 - 2031
    • 6.2.1. Key Highlights
      • 6.2.1.1. Antimicrobial Agents
        • 6.2.1.1.1. Tetracyclines
        • 6.2.1.1.2. Penicillins
        • 6.2.1.1.3. Cephalosporins
        • 6.2.1.1.4. Macrolides
        • 6.2.1.1.5. Quinolones
        • 6.2.1.1.6. Others
      • 6.2.1.2. Antiviral Agents
      • 6.2.1.3. Antifungal Agents
      • 6.2.1.4. Antiparasitic Agents
      • 6.2.1.5. Others
  • 6.3. Asia Pacific Veterinary Anti-Infectives Market Outlook, by Mode of Administration, Value (US$ Mn), 2018 - 2031
    • 6.3.1. Key Highlights
      • 6.3.1.1. Oral
      • 6.3.1.2. Parenteral
      • 6.3.1.3. Topical
  • 6.4. Asia Pacific Veterinary Anti-Infectives Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 6.4.1. Key Highlights
      • 6.4.1.1. Veterinary Hospitals
      • 6.4.1.2. Veterinary Clinics
      • 6.4.1.3. Pharmacies
      • 6.4.1.4. Others
  • 6.5. Asia Pacific Veterinary Anti-Infectives Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 6.5.1. Key Highlights
      • 6.5.1.1. China Veterinary Anti-Infectives Market by Species Type, Value (US$ Mn), 2018 - 2031
      • 6.5.1.2. China Veterinary Anti-Infectives Market Sample Type, Value (US$ Mn), 2018 - 2031
      • 6.5.1.3. China Veterinary Anti-Infectives Market by Mode of Administration, Value (US$ Mn), 2018 - 2031
      • 6.5.1.4. China Veterinary Anti-Infectives Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 6.5.1.5. Japan Veterinary Anti-Infectives Market by Species Type, Value (US$ Mn), 2018 - 2031
      • 6.5.1.6. Japan Veterinary Anti-Infectives Market by Drug Class, Value (US$ Mn), 2018 - 2031
      • 6.5.1.7. Japan Veterinary Anti-Infectives Market by Mode of Administration, Value (US$ Mn), 2018 - 2031
      • 6.5.1.8. Japan Veterinary Anti-Infectives Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 6.5.1.9. South Korea Veterinary Anti-Infectives Market by Species Type, Value (US$ Mn), 2018 - 2031
      • 6.5.1.10. South Korea Veterinary Anti-Infectives Market by Drug Class, Value (US$ Mn), 2018 - 2031
      • 6.5.1.11. South Korea Veterinary Anti-Infectives Market by Mode of Administration, Value (US$ Mn), 2018 - 2031
      • 6.5.1.12. South Korea Veterinary Anti-Infectives Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 6.5.1.13. India Veterinary Anti-Infectives Market by Species Type, Value (US$ Mn), 2018 - 2031
      • 6.5.1.14. India Veterinary Anti-Infectives Market by Drug Class, Value (US$ Mn), 2018 - 2031
      • 6.5.1.15. India Veterinary Anti-Infectives Market by Mode of Administration, Value (US$ Mn), 2018 - 2031
      • 6.5.1.16. India Veterinary Anti-Infectives Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 6.5.1.17. Southeast Asia Veterinary Anti-Infectives Market by Species Type, Value (US$ Mn), 2018 - 2031
      • 6.5.1.18. Southeast Asia Veterinary Anti-Infectives Market by Drug Class, Value (US$ Mn), 2018 - 2031
      • 6.5.1.19. Southeast Asia Veterinary Anti-Infectives Market by Mode of Administration, Value (US$ Mn), 2018 - 2031
      • 6.5.1.20. Southeast Asia Veterinary Anti-Infectives Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 6.5.1.21. Rest of Asia Pacific Veterinary Anti-Infectives Market by Species Type, Value (US$ Mn), 2018 - 2031
      • 6.5.1.22. Rest of Asia Pacific Veterinary Anti-Infectives Market by Drug Class, Value (US$ Mn), 2018 - 2031
      • 6.5.1.23. Rest of Asia Pacific Veterinary Anti-Infectives Market by Mode of Administration, Value (US$ Mn), 2018 - 2031
      • 6.5.1.24. Rest of Asia Pacific Veterinary Anti-Infectives Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 6.5.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Veterinary Anti-Infectives Market Outlook, 2018 - 2031

  • 7.1. Latin America Veterinary Anti-Infectives Market Outlook, by Species Type, Value (US$ Mn), 2018 - 2031
    • 7.1.1. Key Highlights
      • 7.1.1.1. Livestock Animals
      • 7.1.1.2. Companion Animals
  • 7.2. Latin America Veterinary Anti-Infectives Market Outlook, by Drug Class, Value (US$ Mn), 2018 - 2031
    • 7.2.1. Key Highlights
      • 7.2.1.1. Antimicrobial Agents
        • 7.2.1.1.1. Tetracyclines
        • 7.2.1.1.2. Penicillins
        • 7.2.1.1.3. Cephalosporins
        • 7.2.1.1.4. Macrolides
        • 7.2.1.1.5. Quinolones
        • 7.2.1.1.6. Others
      • 7.2.1.2. Antiviral Agents
      • 7.2.1.3. Antifungal Agents
      • 7.2.1.4. Antiparasitic Agents
      • 7.2.1.5. Others
  • 7.3. Latin America Veterinary Anti-Infectives Market Outlook, by Mode of Administration, Value (US$ Mn), 2018 - 2031
    • 7.3.1. Key Highlights
      • 7.3.1.1. Oral
      • 7.3.1.2. Parenteral
      • 7.3.1.3. Topical
  • 7.4. Latin America Veterinary Anti-Infectives Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 7.4.1. Key Highlights
      • 7.4.1.1. Veterinary Hospitals
      • 7.4.1.2. Veterinary Clinics
      • 7.4.1.3. Pharmacies
      • 7.4.1.4. Others
  • 7.5. Latin America Veterinary Anti-Infectives Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 7.5.1. Key Highlights
      • 7.5.1.1. Brazil Veterinary Anti-Infectives Market by Species Type, Value (US$ Mn), 2018 - 2031
      • 7.5.1.2. Brazil Veterinary Anti-Infectives Market by Drug Class, Value (US$ Mn), 2018 - 2031
      • 7.5.1.3. Brazil Veterinary Anti-Infectives Market by Mode of Administration, Value (US$ Mn), 2018 - 2031
      • 7.5.1.4. Brazil Veterinary Anti-Infectives Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 7.5.1.5. Mexico Veterinary Anti-Infectives Market by Species Type, Value (US$ Mn), 2018 - 2031
      • 7.5.1.6. Mexico Veterinary Anti-Infectives Market by Drug Class, Value (US$ Mn), 2018 - 2031
      • 7.5.1.7. Mexico Veterinary Anti-Infectives Market by Mode of Administration, Value (US$ Mn), 2018 - 2031
      • 7.5.1.8. Mexico Veterinary Anti-Infectives Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 7.5.1.9. Argentina Veterinary Anti-Infectives Market by Species Type, Value (US$ Mn), 2018 - 2031
      • 7.5.1.10. Argentina Veterinary Anti-Infectives Market by Drug Class, Value (US$ Mn), 2018 - 2031
      • 7.5.1.11. Argentina Veterinary Anti-Infectives Market by Mode of Administration, Value (US$ Mn), 2018 - 2031
      • 7.5.1.12. Argentina Veterinary Anti-Infectives Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 7.5.1.13. Rest of Latin America Veterinary Anti-Infectives Market by Species Type, Value (US$ Mn), 2018 - 2031
      • 7.5.1.14. Rest of Latin America Veterinary Anti-Infectives Market by Drug Class, Value (US$ Mn), 2018 - 2031
      • 7.5.1.15. Rest of Latin America Veterinary Anti-Infectives Market by Mode of Administration, Value (US$ Mn), 2018 - 2031
      • 7.5.1.16. Rest of Latin America Veterinary Anti-Infectives Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 7.5.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Veterinary Anti-Infectives Market Outlook, 2018 - 2031

  • 8.1. Middle East & Africa Veterinary Anti-Infectives Market Outlook, by Species Type, Value (US$ Mn), 2018 - 2031
    • 8.1.1. Key Highlights
      • 8.1.1.1. Livestock Animals
      • 8.1.1.2. Companion Animals
  • 8.2. Middle East & Africa Veterinary Anti-Infectives Market Outlook, by Drug Class, Value (US$ Mn), 2018 - 2031
    • 8.2.1. Key Highlights
      • 8.2.1.1. Antimicrobial Agents
        • 8.2.1.1.1. Tetracyclines
        • 8.2.1.1.2. Penicillins
        • 8.2.1.1.3. Cephalosporins
        • 8.2.1.1.4. Macrolides
        • 8.2.1.1.5. Quinolones
        • 8.2.1.1.6. Others
      • 8.2.1.2. Antiviral Agents
      • 8.2.1.3. Antifungal Agents
      • 8.2.1.4. Antiparasitic Agents
      • 8.2.1.5. Others
  • 8.3. Middle East & Africa Veterinary Anti-Infectives Market Outlook, by Mode of Administration, Value (US$ Mn), 2018 - 2031
    • 8.3.1. Key Highlights
      • 8.3.1.1. Oral
      • 8.3.1.2. Parenteral
      • 8.3.1.3. Topical
  • 8.4. Middle East & Africa Veterinary Anti-Infectives Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 8.4.1. Key Highlights
      • 8.4.1.1. Veterinary Hospitals
      • 8.4.1.2. Veterinary Clinics
      • 8.4.1.3. Pharmacies
      • 8.4.1.4. Others
  • 8.5. Middle East & Africa Veterinary Anti-Infectives Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 8.5.1. Key Highlights
      • 8.5.1.1. GCC Veterinary Anti-Infectives Market by Species Type, Value (US$ Mn), 2018 - 2031
      • 8.5.1.2. GCC Veterinary Anti-Infectives Market by Drug Class, Value (US$ Mn), 2018 - 2031
      • 8.5.1.3. GCC Veterinary Anti-Infectives Market by Mode of Administration, Value (US$ Mn), 2018 - 2031
      • 8.5.1.4. GCC Veterinary Anti-Infectives Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 8.5.1.5. South Africa Veterinary Anti-Infectives Market by Species Type, Value (US$ Mn), 2018 - 2031
      • 8.5.1.6. South Africa Veterinary Anti-Infectives Market by Drug Class, Value (US$ Mn), 2018 - 2031
      • 8.5.1.7. South Africa Veterinary Anti-Infectives Market by Mode of Administration, Value (US$ Mn), 2018 - 2031
      • 8.5.1.8. South Africa Veterinary Anti-Infectives Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 8.5.1.9. Egypt Veterinary Anti-Infectives Market by Species Type, Value (US$ Mn), 2018 - 2031
      • 8.5.1.10. Egypt Veterinary Anti-Infectives Market by Drug Class, Value (US$ Mn), 2018 - 2031
      • 8.5.1.11. Egypt Veterinary Anti-Infectives Market by Mode of Administration, Value (US$ Mn), 2018 - 2031
      • 8.5.1.12. Egypt Veterinary Anti-Infectives Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 8.5.1.13. Nigeria Veterinary Anti-Infectives Market by Species Type, Value (US$ Mn), 2018 - 2031
      • 8.5.1.14. Nigeria Veterinary Anti-Infectives Market by Drug Class, Value (US$ Mn), 2018 - 2031
      • 8.5.1.15. Nigeria Veterinary Anti-Infectives Market by Mode of Administration, Value (US$ Mn), 2018 - 2031
      • 8.5.1.16. Nigeria Veterinary Anti-Infectives Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 8.5.1.17. Rest of Middle East & Africa Veterinary Anti-Infectives Market by Species Type, Value (US$ Mn), 2018 - 2031
      • 8.5.1.18. Rest of Middle East & Africa Veterinary Anti-Infectives Market by Drug Class, Value (US$ Mn), 2018 - 2031
      • 8.5.1.19. Rest of Middle East & Africa Veterinary Anti-Infectives Market by Mode of Administration, Value (US$ Mn), 2018 - 2031
      • 8.5.1.20. Rest of Middle East & Africa Veterinary Anti-Infectives Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 8.5.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. by Mode of Administration vs by Drug Class Heatmap
  • 9.2. Manufacturer vs by Drug Class Heatmap
  • 9.3. Company Market Share Analysis, 2023
  • 9.4. Competitive Dashboard
  • 9.5. Company Profiles
    • 9.5.1. Bayer AG
      • 9.5.1.1. Company Overview
      • 9.5.1.2. Product Portfolio
      • 9.5.1.3. Financial Overview
      • 9.5.1.4. Business Strategies and Development
    • 9.5.2. Cipla Limited
      • 9.5.2.1. Company Overview
      • 9.5.2.2. Product Portfolio
      • 9.5.2.3. Financial Overview
      • 9.5.2.4. Business Strategies and Development
    • 9.5.3. Dechra Pharmaceuticals PLC
      • 9.5.3.1. Company Overview
      • 9.5.3.2. Product Portfolio
      • 9.5.3.3. Financial Overview
      • 9.5.3.4. Business Strategies and Development
    • 9.5.4. Eli Lilly and Company (Elanco Animal Health)
      • 9.5.4.1. Company Overview
      • 9.5.4.2. Product Portfolio
      • 9.5.4.3. Financial Overview
      • 9.5.4.4. Business Strategies and Development
    • 9.5.5. Heska Corp (Diamond Animal Health)
      • 9.5.5.1. Company Overview
      • 9.5.5.2. Product Portfolio
      • 9.5.5.3. Financial Overview
      • 9.5.5.4. Business Strategies and Development
    • 9.5.6. Merck & Co., Inc. (Merck Animal Health)
      • 9.5.6.1. Company Overview
      • 9.5.6.2. Product Portfolio
      • 9.5.6.3. Financial Overview
      • 9.5.6.4. Business Strategies and Development
    • 9.5.7. Neogen Corporation
      • 9.5.7.1. Company Overview
      • 9.5.7.2. Product Portfolio
      • 9.5.7.3. Financial Overview
      • 9.5.7.4. Business Strategies and Development
    • 9.5.8. Phibro Animal Health Corporation
      • 9.5.8.1. Company Overview
      • 9.5.8.2. Product Portfolio
      • 9.5.8.3. Financial Overview
      • 9.5.8.4. Business Strategies and Development
    • 9.5.9. Sanofi (Merial Animal Health)
      • 9.5.9.1. Company Overview
      • 9.5.9.2. Product Portfolio
      • 9.5.9.3. Financial Overview
      • 9.5.9.4. Business Strategies and Development
    • 9.5.10. Vetoquinol S.A.
      • 9.5.10.1. Company Overview
      • 9.5.10.2. Product Portfolio
      • 9.5.10.3. Financial Overview
      • 9.5.10.4. Business Strategies and Development
    • 9.5.11. Virbac S.A.
      • 9.5.11.1. Company Overview
      • 9.5.11.2. Product Portfolio
      • 9.5.11.3. Financial Overview
      • 9.5.11.4. Business Strategies and Development
    • 9.5.12. Zoetis, Inc.
      • 9.5.12.1. Company Overview
      • 9.5.12.2. Product Portfolio
      • 9.5.12.3. Financial Overview
      • 9.5.12.4. Business Strategies and Development
    • 9.5.13. Boehringer Ingelheim GmbH
      • 9.5.13.1. Company Overview
      • 9.5.13.2. Product Portfolio
      • 9.5.13.3. Financial Overview
      • 9.5.13.4. Business Strategies and Development
    • 9.5.14. Ceva Sante Animale
      • 9.5.14.1. Company Overview
      • 9.5.14.2. Product Portfolio
      • 9.5.14.3. Financial Overview
      • 9.5.14.4. Business Strategies and Development
    • 9.5.15. Indian Immunologicals Limited
      • 9.5.15.1. Company Overview
      • 9.5.15.2. Product Portfolio
      • 9.5.15.3. Financial Overview
      • 9.5.15.4. Business Strategies and Development
    • 9.5.16. Intas Pharmaceuticals Limited
      • 9.5.16.1. Company Overview
      • 9.5.16.2. Product Portfolio
      • 9.5.16.3. Financial Overview
      • 9.5.16.4. Business Strategies and Development
    • 9.5.17. Norbrook Laboratories Limited
      • 9.5.17.1. Company Overview
      • 9.5.17.2. Product Portfolio
      • 9.5.17.3. Financial Overview
      • 9.5.17.4. Business Strategies and Development
    • 9.5.18. Zydus Animal Health Limited
      • 9.5.18.1. Company Overview
      • 9.5.18.2. Product Portfolio
      • 9.5.18.3. Financial Overview
      • 9.5.18.4. Business Strategies and Development
    • 9.5.19. Ashish Life Science Private Limited
      • 9.5.19.1. Company Overview
      • 9.5.19.2. Product Portfolio
      • 9.5.19.3. Financial Overview
      • 9.5.19.4. Business Strategies and Development
    • 9.5.20. Oceanic Pharmachem Private Limited.
      • 9.5.20.1. Company Overview
      • 9.5.20.2. Product Portfolio
      • 9.5.20.3. Financial Overview
      • 9.5.20.4. Business Strategies and Development

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations